PCG
LYEL icon

Private Capital Group’s Lyell Immunopharma LYEL Stock Holding History

Private Capital Group’s Portfolio LYEL Stock Details LYEL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-13
Closed -$1K – 2017
2022
Q1 		$1K Buy
13
+3
+30% +$363 ﹤0.01% 1961
2021
Q4 		$2K Buy
+10
New +$2.23K ﹤0.01% 1803

Other funds holding LYEL

MM
MWG Management Road Town, Tortola, British Virgin Islands $81.3M AUM 2.28% 1-Year Est. Return
A
Apoletto Road Town, Tortola, British Virgin Islands $260M AUM 31.4% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $290M AUM 143.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return
HH
HSG Holding Na, Hong Kong $1.2B AUM 23.01% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Private Capital Group's LYEL Position: Q2 2022 in Review

Private Capital Group sold out of Lyell Immunopharma (LYEL) in Q2 2022, closing a stake of 13 shares — an estimated $1K sold.

Private Capital Group first reported a position in LYEL in Q4 2021 and held it in 2 quarters. The position peaked at $2K in Q4 2021. 75 funds tracked by Wall St. Rank hold LYEL as of Q2 2022.

  • Private Capital Group reported no remaining Lyell Immunopharma position as of Q2 2022 after selling out during the quarter.
  • Private Capital Group sold 13 Lyell Immunopharma shares in Q2 2022, an estimated $1K.
  • Private Capital Group first reported a position in Lyell Immunopharma in Q4 2021 and held it in 2 quarters.
  • Private Capital Group's Lyell Immunopharma position peaked at $2K in Q4 2021.
  • 75 funds tracked by Wall St. Rank held Lyell Immunopharma as of Q2 2022.

Based on Private Capital Group's 13F filing for Q2 2022, filed 28 Jul 2022.